Evotec (NASDAQ:EVO) Reaches New 1-Year Low – Here’s Why

Evotec AG (NASDAQ:EVO)’s stock price reached a new 52-week low during trading on Tuesday . The stock traded as low as $1.80 and last traded at $1.81, with a volume of 28171 shares trading hands. The stock had previously closed at $1.86.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on EVO. Weiss Ratings lowered Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 25th. TD Cowen lowered Evotec from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a research report on Wednesday, July 15th. HC Wainwright lowered their target price on Evotec from $7.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, July 15th. Finally, Berenberg Bank downgraded shares of Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $3.00.

Evotec Price Performance

The firm has a fifty day simple moving average of $2.09 and a two-hundred day simple moving average of $2.58. The company has a current ratio of 2.33, a quick ratio of 2.21 and a debt-to-equity ratio of 0.62.

Institutional Investors Weigh In On Evotec

Several institutional investors have recently added to or reduced their stakes in EVO. Wellington Management Group LLP boosted its position in Evotec by 25.7% during the fourth quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock worth $5,536,000 after purchasing an additional 367,545 shares during the period. WCM Investment Management LLC lifted its stake in shares of Evotec by 12.1% during the 1st quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock valued at $1,480,000 after buying an additional 67,917 shares in the last quarter. Optiver Holding B.V. lifted its stake in shares of Evotec by 598.4% during the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock valued at $709,000 after buying an additional 242,973 shares in the last quarter. Jane Street Group LLC bought a new position in Evotec in the 4th quarter worth approximately $565,000. Finally, Millennium Management LLC bought a new position in Evotec in the 4th quarter worth approximately $317,000. 5.81% of the stock is owned by hedge funds and other institutional investors.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.